Proof-of-Concept Trial on Selective Removal of sFlt-1 in Pregnant Women With Preeclampsia Via Apheresis (SAVE)
Proof-of-Concept Trial on Selective Removal of the Antiangiogenic Factor Soluble Fms-like Tyrosine Kinase-1 (sFlt-1) in Pregnant Women With Preeclampsia Via Apheresis Utilizing the Flt-1 Adsorption Column
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Jörg Liebmann, PhD
- Email: joergli@miltenyi.com
Study Locations
-
-
-
Cologne, Germany, 50937
- Universitätsklinikum Köln
-
Leipzig, Germany, 04103
- Universitatsklinikum Leipzig
-
-
-
-
-
Cambridge, United Kingdom, CB2 0QQ
- Cambridge Clinical Trials Unit, Addenbrooke's Hospital
-
Oxford, United Kingdom, OX3 9DU
- Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Reduced criteria!
Phase 0
Inclusion Criteria:
- Age ≥18 and ≤45 years;
- Male or female;
- Female subjects of childbearing potential must have a negative serum pregnancy test result at screening and practice two reliable methods of contraception throughout the study.
Exclusion Criteria:
- Dysfunction of cerebral nervous system and/or heart disease;
- History of preexisting chronic renal disease;
- Treatment with ACE inhibitors;
- Therapeutic full anticoagulation therapy prior to trial entry;
- Liver abnormalities;
- Clinically significant pulmonary edema and/or thrombocytopenia and/or anemia;
- Active hepatitis B, C, or tuberculosis infection or HIV infection
- Hypersensitivity to heparin and/or citrate;
- Indications that prohibit transient anticoagulation using heparin and/or ACD-A-solutions;
- Known intolerance to extracorporeal procedures in general or towards one of the individual excipients or towards other supporting agents;
- Drug or alcohol abuse within the last 2 years;
- Lack of compliance of subject;
- History or diagnosis of severe periodontitis;
Phase A and B
Inclusion Criteria:
- Age >18 and ≤45 years ;
- Pregnant woman with pre-term preeclampsia
- sFlt-1/PlGF ratio ≥85 ;
- sFlt-1 level of ≥ 8000pg/mL
Exclusion Criteria:
Maternal exclusion criteria
- History of cardiac impairments including uncontrolled arrhythmia, unstable angina, decompensated congestive heart failure or valve disease;
- History of preexisting chronic renal disease (CKD stage >3a, eGFR ≤45ml/min/1.73m²);
- Treatment with ACE inhibitors;
- Therapeutic full anticoagulation therapy prior to trial entry;
- Signs or history of clinically significant cerebral nervous system dysfunction;
- History of clinically significant liver abnormalities;
- Clinically significant pulmonary edema and/or thrombocytopenia and/or anemia;
- Active hepatitis B, C, tuberculosis infection or HIV-positive status;
- Any condition that the investigator deems a risk to the patient or fetus in completing the trial;
- Indications that prohibit transient anticoagulation using heparin and/or ACD-A-solutions;
- Drug or alcohol abuse within the last 2 years;
- Lack of compliance of patient;
- Known intolerance to extracorporeal procedures in general or to one of the excipients or other supporting agents;
- Hypersensitivity to heparin and/or citrate;
- < 30 0/7 weeks of gestation and abnormal CTG and/or abnormal Ductus venosus Doppler flow,
- ≥30 0/7 weeks of gestation and Doppler evidence of umbilical artery Absent or Reversed End-Diastolic Velocity (AREDV);
- Various Placental exclusion criteria;
- Multiple pregnancy
- History or diagnosis of severe periodontitis
Fetal exclusion criteria
- Any known trisomy;
- Amniotic fluid index <5cm (greatest single pocket <2cm);
- Estimated fetal weight <3rd percentile for gestational age;
- Fetus which are at high risk of heart disease;
- Fetus with congenital heart defect;
- Fetal signs of bleeding;
- Hydrops fetalis;
- Pathological fetal Doppler flow of the ductus venosus (absent A-wave in two measurements);
- Evidence of severe fetal malformations;
- Known infection of fetus;
- Known severe anemia.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Phase 0 - healthy volunteers
Phase 0 is an initial safety phase where subjects will undergo one single TheraSorb sFlt-1 adsorber apheresis procedure.
|
Removal of excessive sFlt-1 from the plasma of subjects/ patients with therapeutic apheresis.
|
|
Experimental: Phase A - preeclampsia patients
Phase A is a safety and dose-finding phase during which pregnant women diagnosed with preeclampsia will undergo one single TheraSorb sFlt-1 adsorber apheresis procedure.
|
Removal of excessive sFlt-1 from the plasma of subjects/ patients with therapeutic apheresis.
|
|
Experimental: Phase B - preeclampsia patients
Phase B is a safety and efficacy phase during which pregnant women diagnosed with preeclampsia will undergo TheraSorb sFlt-1 adsorber apheresis procedures up to twice weekly.
|
Removal of excessive sFlt-1 from the plasma of subjects/ patients with therapeutic apheresis.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Occurrence of AEs and SAEs in healthy volunteers until the 2 weeks follow-up (Phase 0)
Time Frame: until 2 weeks post treatment
|
until 2 weeks post treatment
|
|
Occurrence of AEs and SAEs in pregnant subjects and the fetus or infant until the 6 weeks post-delivery visit is reached (Phase A-B).
Time Frame: until 6 weeks post delivery
|
until 6 weeks post delivery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Phase 0: Determine changes of sFlt-1 levels.
Time Frame: until 2 weeks post treatment
|
until 2 weeks post treatment
|
|
Phase 0: Complement activation levels pre-, during and post apheresis.
Time Frame: Before, during and directly following the performance of the single apheresis treatment (1 day)
|
Before, during and directly following the performance of the single apheresis treatment (1 day)
|
|
Phase 0: Concentration of antibody leaching during an apheresis procedure
Time Frame: During an apheresis procedure (1 day)
|
During an apheresis procedure (1 day)
|
|
Phase 0: Change of HAMA levels in pre- and post apheresis blood
Time Frame: until 2 weeks post treatment
|
until 2 weeks post treatment
|
|
Phase 0: Evaluate blood pressure values
Time Frame: until 2 weeks post treatment
|
until 2 weeks post treatment
|
|
Phase 0: Evaluate spot urine values
Time Frame: until 2 weeks post treatment
|
until 2 weeks post treatment
|
|
Phase A/B: Occurrence of SAEs in the one year follow-up period
Time Frame: until end of FU, (1 year)
|
until end of FU, (1 year)
|
|
Phases A/B: Evaluate antibody leaching in phase A.
Time Frame: During the performance of the single apheresis treatment in Phase A (1 day) as well as pre and 3hrs post apheresis
|
During the performance of the single apheresis treatment in Phase A (1 day) as well as pre and 3hrs post apheresis
|
|
Phases A and B: Evaluate maternal sFlt-1 levels.
Time Frame: Constant measures throughout the trial until delivery (up to 19 weeks)
|
Constant measures throughout the trial until delivery (up to 19 weeks)
|
|
Phases A/B: Evaluate the sFlt-1/PlGF ratio.
Time Frame: Constant measures throughout the trial until delivery (up to 19 weeks)
|
Constant measures throughout the trial until delivery (up to 19 weeks)
|
|
Phases A/B:Evaluate neonatal umbilical cord blood sFlt-1 levels at birth.
Time Frame: at birth
|
at birth
|
|
Phases A/B: Determine HAMA levels
Time Frame: until 6 week FU visit
|
until 6 week FU visit
|
|
Phases A/B: Time and method of delivery, and anesthesia administered
Time Frame: at birth
|
at birth
|
|
Phases A and B: Determine the post-partum maternal and neonatal length of hospitalization.
Time Frame: Following birth up to one year
|
Following birth up to one year
|
|
Phases A/B: Evaluate standard markers of fetal development throughout pregnancy.
Time Frame: From start of trial until delivery (up to 19 weeks)
|
From start of trial until delivery (up to 19 weeks)
|
|
Phases A/B: Evaluate standard markers of neonatal development.
Time Frame: Directly following delivery until end of FU (1 year)
|
Directly following delivery until end of FU (1 year)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Thomas Benzing, Prof. Dr., University Clinic Cologne
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- M-2016-313
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.